A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
- 27 August 2007
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 362 (4), 816-821
- https://doi.org/10.1016/j.bbrc.2007.08.051
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Activation of Ubiquitin Ligase SCFSkp2 by Cks1: Insights from Hydrogen Exchange Mass SpectrometryJournal of Molecular Biology, 2006
- The Consensus Coding Sequences of Human Breast and Colorectal CancersScience, 2006
- Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung CancerPLoS Medicine, 2006
- Structural Basis for Defects of Keap1 Activity Provoked by Its Point Mutations in Lung CancerMolecular Cell, 2006
- The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional ActivationMolecular and Cellular Biology, 2005
- Nrf2 Controls Constitutive and Inducible Expression of ARE-driven Genes through a Dynamic Pathway Involving Nucleocytoplasmic Shuttling by Keap1Journal of Biological Chemistry, 2005
- Keap1 Regulates the Oxidation-Sensitive Shuttling of Nrf2 into and out of the Nucleus via a Crm1-Dependent Nuclear Export MechanismMolecular and Cellular Biology, 2005
- Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase ComplexMolecular and Cellular Biology, 2004
- Nrf2, a Cap'n'Collar Transcription Factor, Regulates Induction of the Heme Oxygenase-1 GeneJournal of Biological Chemistry, 1999
- Free radicals and anticancer drug resistance: Oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumorsFree Radical Biology & Medicine, 1990